Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Deal, Chad L., Mitlak, Bruce H., Wang, Yamei, Fitzpatrick, Lorraine A., Miller, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883300/
https://www.ncbi.nlm.nih.gov/pubmed/31799340
http://dx.doi.org/10.1016/j.bonr.2019.100230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883300/
https://www.ncbi.nlm.nih.gov/pubmed/31799340
http://dx.doi.org/10.1016/j.bonr.2019.100230

Ejemplares similares